Fidelis Capital Partners LLC Sells 118 Shares of Becton, Dickinson and Company (NYSE:BDX)

Fidelis Capital Partners LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 10.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 974 shares of the medical instruments supplier’s stock after selling 118 shares during the period. Fidelis Capital Partners LLC’s holdings in Becton, Dickinson and Company were worth $227,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Jennison Associates LLC raised its holdings in Becton, Dickinson and Company by 4.9% in the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after acquiring an additional 18,786 shares during the period. Norden Group LLC increased its stake in shares of Becton, Dickinson and Company by 2,086.7% during the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock worth $12,853,000 after purchasing an additional 49,559 shares during the period. Franklin Street Advisors Inc. NC acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth approximately $11,998,000. Avity Investment Management Inc. boosted its stake in Becton, Dickinson and Company by 3.5% in the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after purchasing an additional 5,527 shares during the period. Finally, Caden Capital Partners LP grew its holdings in Becton, Dickinson and Company by 26.7% in the 4th quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock valued at $20,340,000 after buying an additional 17,599 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

BDX has been the subject of a number of research reports. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup decreased their target price on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Raymond James reduced their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, Evercore ISI dropped their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Stock Up 0.5 %

Shares of BDX opened at $234.70 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $269.52. The stock has a market capitalization of $67.83 billion, a price-to-earnings ratio of 51.70, a PEG ratio of 1.91 and a beta of 0.42. The stock has a fifty day moving average of $235.68 and a 200-day moving average of $235.52.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter in the prior year, the firm earned $2.96 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.